Uni Drug
Concise Prescribing Info
Atorvastatin Ca
Adjunct to diet for the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B & triglycerides in patients w/ primary hypercholesterolemia, heterozygous familial hypercholesterolemia or combined (mixed) hyperlipidemia (Fredrickson types IIa & IIb), elevated serum triglyceride levels (Fredrickson type IV) & those w/ dysbetalipoproteinemia (Fredrickson type III) when response to diet & other non-pharmacological measures is inadequate. Raises HDL-cholesterol & lowers LDL/HDL & total cholesterol/HDL ratios. Adjunct to diet & other nondietary measures in reducing elevated total cholesterol, LDL-cholesterol & apolipoprotein B in patients w/ homozygous familial hypercholesterolemia when response to these measures is inadequate. Reduces the risk of MI in adult hypertensive patients w/o clinically evident CHD, but w/ at least 3 additional risk factors for CHD eg, age ≥55 yr, male sex, smoking, left ventricular hypertrophy, other specified abnormalities on ECG, microalbuminuria or proteinuria, ratio of plasma total cholesterol to HDL-cholesterol ≥6 or premature family history of CHD. Reduces the risk of MI or stroke in patients w/ type 2 diabetes & w/o clinically evident CHD, but w/ multiple risk factors for CHD eg, retinopathy, albuminuria, smoking or HTN. Reduces the risk of nonfatal MI, fatal & nonfatal stroke, revascularization procedures, hospitalization for CHF & angina in patients w/ clinically evident CHD.
Dosage/Direction for Use
Initially 10 mg once daily. Dose may be adjusted at intervals of ≥4 wk. Max: 80 mg daily. Primary hypercholesterolemia & combined (mixed) hyperlipidemia 10 mg once daily for 2-4 wk. Homozygous familial hypercholesterolemia 80 mg. Prevention of CV disease Primary: 10 mg daily.
May be taken with or without food: May take w/o regard to time of day. Avoid excessive consumption (>1 L/day) of grapefruit juice. 
Hypersensitivity. Active liver disease or unexplained persistent elevations of serum transaminases >3 times the upper limit of normal (ULN); myopathy. Women of childbearing potential not using appropriate contraceptive measures. Pregnancy & lactation.
Special Precautions
Perform liver function tests prior to initiation of treatment & periodically thereafter. Haemorrhagic stroke or lacunar infarct. Measure creatine phosphokinase (CPK) prior to treatment in patients w/ renal impairment, hypothyroidism; history of hereditary muscular disorders, muscular toxicity w/ statins or fibrates, liver disease &/or substantial alcohol consumption, elderly >70 yr. Discontinue use if significant CPK elevation (>5 times ULN) or if muscular symptoms are severe even if the CPK levels are elevated to ≤5 times ULN, or if clinically significant elevation of CPK levels (>10 times ULN) occurs or if rhabdomyolysis is diagnosed or suspected. Temporarily w/hold or discontinue treatment in patients w/ acute, serious condition suggestive of a myopathy or w/ risk factor predisposing to renal failure secondary to rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders, & uncontrolled seizures). Concomitant use w/ ciclosporin, erythromycin, clarithromycin, itraconazole, ketoconazole, nefazodone, niacin, gemfibrozil, other fibric acid derivatives or HIV-PIs; ezetimibe. Patients <18 yr (for treatment periods >52 wk). Childn <10 yr & premenarchal girls. Long-term effects on cognitive development, growth & pubertal maturation. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Adverse Reactions
Abdominal pain, constipation, flatulence, dyspepsia, nausea, diarrhoea; allergic reactions; insomnia; headache, dizziness, paraesthaesia, hypoesthesia; skin rash, pruritus; myalgia, arthralgia, back pain; asthenia, chest pain, peripheral oedema.
Drug Interactions
Increase on the following: Risk of myopathy w/ ciclosporin, gemfibrozil/fibric acid derivatives, macrolides including erythromycin, azole antifungals, HIV-PIs or niacin, ezetimibe; plasma conc w/ CYP3A4 inhibitors (eg, clarithromycin, nefazodone, itraconazole); systemic exposure w/ OATP1B1 & P-glycoprotein transporter inhibitors; AUC w/ ritonavir + saquinavir, or w/ diltiazem or grapefruit juice; exposure w/ verapamil, amiodarone, amlodipine. Variable reductions in plasma conc w/ CYP3A4 inducers eg, efavirenz, rifampin, St. John's wort. Increases digoxin conc, norethindrone, ethinyl oestradiol. Decreased plasma conc but greater lipid effects w/ colestipol. Decreased plasma conc w/ Mg- & Al hydroxide-containing antacids. May affect prothrombin time w/ warfarin.
ATC Classification
C10AA05 - atorvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
Atoris FC tab 10 mg
Atoris FC tab 20 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in